

# Luncheon Symposium 4

---

## Chairperson

---

**Hyun Ho Shin**

Asan Chungmu Hospital, Korea

---

## Speaker

---

**Kyoung Min Kim**

Yonsei University, Korea



## Kyoung Min Kim

Yonsei University, Korea

### • Education

Period	Affiliation	Position
– 2009-2012	College of Medicine, Yonsei University, Korea	Ph.D.
– 2006-2008	College of Medicine, Yonsei University, Korea	M.S.
– 1998-2004	College of Medicine, Yonsei University, Korea	M.D.

### • Affiliations / Experience

Period	Affiliation	Position
– 2020-Present	Yongin Severance Hospital/ Yonsei University College of Medicine	Associate Professor
– 2019-2020	San Francisco Coordinating Center, California Pacific Medical Center Research Institute, UCSF, USA	Associate Scientist
– 2013-2020	Internal Medicine, Seoul National University Bundang Hospital, Korea	Assistant Professor
– 2010-2013	Internal Medicine, Yonsei University College of Medicine, Severance Hospital	Clinical Research Assistant Professor
– 2009-2010	Internal Medicine, Yonsei University College of Medicine, Severance Hospital	Clinical Fellow (Endocrinology)
– 2005-2009	Internal Medicine, Yonsei University College of Medicine, Severance Hospital	Residency

### • Committee Memberships

- Korean Society of Health Informatics and Statistics
- Korean Society of Bone Metabolism and Research
- Korean Sarcopenia Research Group
- Big Data Committee, International Federation of Musculoskeletal Research
- Korean Endocrine Society, Korean Diabetic Association

### • Publications

- Lee S, MH Yu, N Hong, KJ Kim, HK Kim, Y Rhee, M Lee, KM Kim. Association of Sodium-Glucose Cotransporter 2 inhibitor use with risk of osteoporotic fracture among older women: A nationwide, population-based cohort study. *Diabetes Res Clin Pract.* 2024 May 18, 111712 e-pub
- Kim KM, Kim KJ (Co-first\*), Han K, Rhee Y. Associations Between Physical Activity and the Risk of Hip Fracture Depending on Glycemic Status: A Nationwide Cohort Study. *J Clin Endocrinol Metab.* 2024 Feb 20;109(3):e1194-e1203
- Hong N, Cho SW, Shin S, Lee S, Jang SA, Roh S, Lee YH, Rhee Y, Cummings SR, Kim H, Kim KM. Deep-Learning-Based Detection of Vertebral Fracture and Osteoporosis Using Lateral Spine X-Ray Radiography. *Journal of Bone and Mineral Research.* 2023 Apr 10
- Kim KM, Lui LY, Cummings SR. Recent Fall and High Imminent Risk of Fracture in Older Men and Women, Recent fall and imminent risk of fracture. *Age Ageing.* 2022 Jun 1;51(6):afac141
- Kim KM, Nerlekar Ridhima, Tranah GJ, Browner WS, Cummings SR. Higher red cell distribution width and poorer hospitalization-related outcomes in elderly patients. *J Am Geriatr Soc.* 2022;70:2354–2362. PMID: 3550625
- Kim KM, Lui LY, Browner WS, Cauley JA, Ensrud KE, Kado DM, Orwoll ES, Schousboe JT, Cummings SR; Osteoporotic Fractures in Men (MrOS) Study Research Group. Association between variation in red cell size and multiple aging-related outcomes. *J Gerontol A Biol Sci Med Sci.* 2021 Jun 14;76(7):1288-1294. doi: 10.1093/gerona/glaa217. PMID: 32894755
- Jang SA, Kwon SJ, Kim CS, Park SW, Kim KM(Correspondence). Association Between Low Serum Phosphate Level and Risk of Falls in Hospitalized Patients Over 50 Years of Age: A Retrospective Observational Cohort Study. *Clin Interv Aging.* 2022 Sep 8;17:1343-1351

## Luncheon Symposium 4

# Real World Evidence of Phentermine Plus Topiramate ER in Korean : Efficacy and Safety

Kyoung Min Kim (Yonsei University, Korea)

---

Obesity is a critical public health issue, associated with significant morbidity and healthcare system burden. Phentermine/topiramate extended release (ER) has emerged as a key pharmacological intervention in obesity management. This lecture explores the clinical application of phentermine/topiramate ER, focusing on its efficacy and safety through patient case studies and real-world data from Korea.

The presentation will highlight diverse cases of obese patients, each demonstrating unique aspects of weight management using phentermine/topiramate ER. These cases will showcase the drug's impact on weight reduction, health improvements, and potential side effects across various obesity-related comorbidities.

Complementing individual cases, recent analyses of real-world data from Korea will provide broader insights into the drug's use in obesity treatment. This comprehensive view, derived from observational studies and post-marketing surveillance, will offer valuable perspectives on the drug's effectiveness, safety profile, and role in obesity management strategies.

While advances in anti-obesity pharmacotherapy are promising, obesity treatment remains challenging due to limited therapeutic options and frequent adverse reactions. However, the combination of recent clinical experiences and Korean data is expected to provide new insights into the optimal use of phentermine/topiramate ER for successful weight management.